Ariana Pelosci

Patients with intermediate- or high-risk primary or secondary myelofibrosis with a low platelet count may derive benefit from treatment with pacritinib following its accelerated approval by the FDA.

Patients with heavily pretreated relapsed/refractory multiple myeloma may now receive treatment with ciltacabtagene autoleucel following its approval by the FDA.

Jun Gong, MD, hosted a Twitter takeover during the 2022 Genitourinary Cancers Symposium where he discussed breaking presentations in a #CNRealtimeReport.

Based on results from the CheckMate-816 trial, the FDA has accepted a supplemental biological license agreement for nivolumab plus chemotherapy for patients with resectable non–small cell lung cancer.

Younger survivors of B-cell non-Hodgkin lymphoma appeared to have an increased risk of adverse health outcomes 5 or more years after diagnosis compared with older survivors.

A presentation from the 2022 ASTRO Multidisciplinary Head and Neck Cancers Symposium showed a de-escalated radiotherapy dose to 54 Gy vs 70 Gy led to better measures of toxicity in those with p16+ oropharyngeal squamous cell carcinoma.

Findings from a systematic review that evaluated bevacizumab, trastuzumab, and rituximab vs respective biosimilars highlighted little difference in outcomes between treatment options.

Findings indicate that patients with advanced or metastatic radioactive iodine–refractory differentiated thyroid cancer who received apatinib experienced a prolonged survival benefit vs placebo.

The TERAVOLT study identified 7 factors associated with increased mortality risk for patients with thoracic malignancies who have contracted COVID-19.

The CheckMate 648 trial found that using a combination of nivolumab and chemotherapy or nivolumab plus ipilimumab vs chemotherapy alone improved survival in advanced esophageal squamous-cell carcinoma.

OQ011, a topical ointment for hand-foot skin reaction-related pain, yielded positive safety and efficacy in part 1 of 2 phase 2 NOVA-II trial.

Patients who underwent allogeneic hematopoietic cell transplantation using younger matched unrelated donors had a better disease-free survival compared who those who used older matched sibling donors.

The recommended dose of ceritinib once daily with food demonstrated promising preliminary clinical activity in patients with ALK-positive relapsed/recurrent inflammatory myofibroblastic tumors and anaplastic large cell lymphoma, and certain subsets of relapsed/refractory neuroblastoma.

The FDA has granted IO-202, a LILRB4 checkpoint inhibitor, fast track designation for the treatment of relapsed or refractory acute myeloid leukemia.

A new drug application has been accepted by the FDA for poziotinib in patients with advanced or metastatic non–small cell lung cancer with HER2 exon 20 insertion mutations.

The phase 3b PRESIDE trial showed significant progression-free survival improvement when men with chemotherapy-naïve metastatic castration-resistant prostate cancer were treated with a regimen of continuous enzalutamide vs placebo.

The FoundationOne Tracker ctDNA monitoring assay was given breakthrough device designation by the FDA for use in early-stage cancer after curative therapy.

Patients with prostate cancer commonly have significant depression, highlighting a need for screenings in those with poor social determinants of health, concomitant disability, and advanced disease.

Fast track designation was granted by the FDA for pidnarulex in patients with BRCA1/2 or PALB2 mutations with ovarian or breast cancer.

Cancer misinformation may be more prevalent among residents in rural vs urban areas, study finds.

A combination of sitting for longer periods a day and a lack of physical activity resulted in a higher risk of death than those who partook in physical activity.

A phase 2/3 trial found that patients with low-grade serous ovarian cancer treated with trametinib had improved survival over the standard of care.

Patients with metastatic castration-resistant prostate cancer treated with apalutamide and prednisone experienced a better radiographic progression-free survival vs an active and established comparator regimen.

The phase 2 PERMEATE trial yielded positive results in the combination of pyrotinib plus capecitabine in patients with HER2-positive breast cancer and brain metastases.

In patients with completely resected non–small cell lung cancer with mediastinal N2 involvement, postoperative radiotherapy was not associated with an increase in disease-free survival.

Treatment with armodafinil did not result in a significant difference in cancer-related fatigue between treatment arms for patients with high-grade glioma.

Consolidation therapy with bortezomib, lenalidomide, and dexamethasone plus lenalidomide maintenance improved progression-free survival in patients with newly diagnosed multiple myeloma.

Patients with HER2-positive breast cancer who were treated with trastuzumab deruxtecan experienced favorable activity and reduction or loss of HER2 expression.

According to a study conducted at a single cancer center in Southern Maryland, patients who survived breast or prostate cancer were less likely to receive a colorectal cancer screening.

Experts explored existing data to create a universal definition of integrative oncology, in tandem with feedback from Society of Integrative Oncology, to better explains what the term means.